Evidence map›Paper›PMID 29781056›Full record

ArticleInvestigational new drugs2019

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.

A Craig Lockhart, Todd M Bauer, Charu Aggarwal, Carrie B Lee, R Donald Harvey, Roger B Cohen, Farhad Sedarati, Tsz Keung Nip, Hélène Faessel, Ajeeta B Dash and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01862328 (A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors), which is not on this map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01862328 phase1completednot on this map

A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

TypeinterventionalSponsorMillennium Pharmaceuticals, Inc.Ran2013 to 2018Enrolled64ConditionsSolid TumorsArmsMLN4924, Paclitaxel, Gemcitabine, Docetaxel, Carboplatin
3 · Its place in the literature

Who cites it

53 citing papers in PubMed.

  1. Review
  2. Review
  3. Targeting ubiquitination in disease and therapy.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Inhibiting neddylation: A new strategy for tumor therapy.Journal of pharmaceutical analysis · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A Craig LockhartDivision of Medical Oncology, University of Miami/Sylvester Comprehensive Cancer Center, 1120 NW 14th Street, Suite 650L, Miami, FL, USA. aclockhart@med.miami.edu.ORCID 0000-0002-0132-5523
Todd M BauerDrug Development, Sarah Cannon Research Institute/Tennessee Oncology PLLC., Nashville, TN, USA.
Charu AggarwalDivision of Hematology-Oncology, Department of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Carrie B LeeDivision of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
R Donald HarveyDepartments of Hematology and Medical Oncology and Pharmacology, Emory University School of Medicine, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Roger B CohenDepartment of Medicine, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Farhad SedaratiOncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Tsz Keung NipBiostatistics, Takeda Development Centre EU, London, UK.
Hélène FaesselQuantitative Clinical Pharmacology, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Ajeeta B DashTranslational and Biomarker Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Bruce J DezubeOncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Douglas V FallerOncology Clinical Research, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA.
Afshin DowlatiDepartment of Medicine, Case Western Reserve University, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclitaxel (arm 2, n = 26), or gemcitabine (arm 3, n = 10) in 21-days (arms 1 and 2) or 28-days (arm 3) cycles. A lead-in cohort (arm 2a, n = 6) determined the arm 2 carboplatin dose. Dose escalation proceeded via continual modified reassessment. Results Pevonedistat MTD was 25 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCohort StudiesCyclopentanesDeoxycytidineDocetaxelFemaleFollow-Up StudiesGemcitabineHumansMaleMaximum Tolerated DoseMiddle AgedCarboplatinCyclopentanesDeoxycytidineDocetaxelGemcitabineNEDD8 ProteinNEDD8 protein, humanPaclitaxelpevonedistatPyrimidinesAdvanced solid tumorsClinical researchPevonedistatPhase Ib studyStandard-of-care chemotherapies

Identifiers

PMID29781056
PMCPMC6510847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.